Durability of the First Biologic in Patients with Crohn's Disease: A Nationwide Study from the epi-IIRN.

Background In this nationwide study we aimed to compare the durability of the first initiated biologic in Crohn's disease [CD], stratified by monotherapy and combotherapy. Methods We used data from the epi-IIRN cohort, which includes 98% of the Israeli inflammatory bowel disease population [2005–2020]. Durability was defined as consistent treatment without surgery or added medications [except for combination therapy with thiopurines or methotrexate]. All comparisons were based on stringent propensity-score matching and paired time-to-event analyses. Results A total of 19 264 patients with CD were included, of whom 7452 [39%] received biologics with a median follow-up of 6.8 years (interquartile range [IQR] 3.6–10.7). Time to biologics decreased gradually from 6.7 years [IQR 2.7–10.4] in 2005 to 0.2 years [0.07–0.23] in 2020. The durability of the first biologic after 1 and 3 years was higher with adalimumab monotherapy [88%/61%] than vedolizumab monotherapy [81%/59%; n  = 394 matched patients, p  = 0.04] and similar between infliximab monotherapy and vedolizumab monotherapy [65%/43%; n  = 182 matched patients, p  = 0.1]. Durability was higher in adalimumab monotherapy vs infliximab monotherapy [83%/62% vs 71%/48% at 1/3 years; p  <0.001] and it was similar in adalimumab monotherapy vs infliximab combotherapy [87%/63% vs 80%/58%, respectively; p  = 0.1]. Durability was higher in combotherapy compared with monotherapy for both infliximab [85%/64% vs 67%/43%, respectively; n  = 496 matched pairs, p  <0.001], and adalimumab [93%/76% vs 82%/62%, respectively; n  = 540 matched pairs, p  <0.001]. Conclusion Durability of the first biologic in CD was highest for adalimumab monotherapy. Combotherapy further increased the durability of adalimumab and infliximab. Unless otherwise indicated, our data may support using anti-tumour necrosis factors [TNFs] as first-line biologics in CD, particularly adalimumab if monotherapy is advised. [ABSTRACT FROM AUTHOR]